|
|
Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation.
MSCs are an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications. Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth.
Naturally, a broad range of research products have been developed around MSCs and their differentiated cell types. Growing attention is also being given to manufacturing technologies to support commercial-scale production of MSCs. MSCs are well-suited for use in the exponential growth field of 3D printing, because of their capacity to form structural tissues.
Numerous market competitors are exploring commercialization strategies for MSC-derived extracellular vesicles (EVs) and exosomes, because these extracellular “packages” represent a novel strategy for accessing the therapeutic effects of stem cells without the risks of administering whole cells to patients.
MSCs are also an intriguing tool for the treatment of complications related to COVID-19 as well. This is because MSCs exert powerful immunomodulatory effects when administered intravenously. Potential mechanisms of action include improving the lung microenvironment, inhibiting immune system over-activation, promoting tissue repair, protecting lung alveoli epithelial cells, preventing pulmonary fibrosis, and improving lung function.
Finally, gene editing of MSCs for overexpressing antitumor genes or therapeutic factors is broadening their application.
MSCs, the Leading Stem Cell Type Being Used in Regenerative Medicine Today
As the most common stem cell type being used within regenerative medicine today, there is vast potential for growth within the MSC market. Today there are an astounding 108,637 scientific publications published about MSCs. There are also at least 1,670 MSC clinical trials underway worldwide. Current “hotspots” for MSC clinical trials include the U.S., E.U., China, Middle East, and South Korea.
While countless early-stage MSC trials have demonstrated safety and efficacy, only a small number of MSC products have reached commercialization, indicating that the therapeutic market for MSCs remains early-stage. There are now 12 MSC-based therapies have been approved globally, with five (42.7%) of those approvals happening within the Republic of Korea (Queencell from Anterogen, Cellgram AMI from Pharmicell, Cupistem from Anterogen, Cartistem from Medipost, and NeuroNataR from Corestem).
Japan has also approved two MSC products, as has the EU. India, Iran, and Australia have each approved one MSC product. Interestingly, the U.S. has yet to approve an MSC product, although the U.S. FDA is actively evaluating Mesoblast’s Remestemcel-L, which has received an RMAT designation from the FDA.
Population aging and an increasing prevalence of chronic disease are also driving interest in MSC-based therapies. Furthermore, Google Trend data reveals that MSC searches are more than twice as common as any other stem cell type.
The demand for MSCs and MSC-related research products has surged in recent years, with nearly a hundred market competitors now developing products/services, therapies, and manufacturing technologies specific to MSCs. Within this ever-changing landscape, having a thorough understanding of the market competition and their relative strengths and weaknesses is essential.
While therapeutic success has been challenging, the demand for MSC-based research products has risen with most large research product suppliers now offering a variety of MSC-based products, services, kits, and manufacturing tools. To date, the company to establish itself with the greatest domain knowledge in the area of MSC-based products and manufacturing technologies is RoosterBio, headquartered in Frederick, Maryland, USA. RoosterBio has substantially enhanced accessibility to high-quality MSCs through innovations in supply chain industrialization, standardized cell bank formats, and cGMP-compatible cells and media systems designed for specific research purposes.
Other major players involved in the market for MSC-based research products include Lonza, Thermo Fisher Scientific, Sigma Aldrich, VWR, Sartorius, ATCC, EMD Millipore, and others. Smaller and mid-sized players are also competing in this promising market, including but not limited to Axol Bioscience, StemBioSys, PromoCell, ScienCell Research Laboratories, and iXCell Biotechnologies.
MSC-Derived Exosomes
Several companies are now developing MSC-derived exosomes for a variety of therapeutic and research applications. Some of the leading companies in this area include:
- Codiak BioSciences – Focused on exosome-based therapeutics, Codiak is advancing MSC-derived exosome technologies for drug delivery and regenerative medicine.
- PureTech Health – Through its subsidiary, Akcea Therapeutics, PureTech is developing exosome-based therapies, including MSC-derived exosomes for targeted drug delivery.
- Capricor Therapeutics – Known for its exosome technology platform, Capricor is developing MSC-derived exosomes for cardiovascular and other therapeutic indications.
- TissueGene – A leader in cell therapy, TissueGene is working on MSC-derived exosomes for use in regenerative medicine, particularly for joint and cartilage repair.
- Exosome Sciences (a subsidiary of Aethlon Medical) – Specializing in exosome-based diagnostics and therapies, Exosome Sciences is exploring MSC-derived exosomes for cancer immunotherapy and other medical applications.
- Exosome Plus – Focuses on MSC-derived exosome research and development, with applications ranging from wound healing to tissue regeneration.
These companies are leveraging the unique properties of MSC-derived exosomes, such as their ability to carry bioactive molecules that modulate immune responses, promote tissue repair, and deliver therapeutic cargo, making them promising tools in drug delivery, regenerative medicine, and immunotherapy.
Emerging Applications for MSCs
MSCs are increasingly being used in other emerging areas of science and medicine as well. For example, the ability of MSCs to differentiate into multiple cell types, including bone, cartilage, and adipose tissue, makes them excellent candidates for bioprinting, allowing them to be incorporated into bioinks to construct complex, functional structures. This is especially valuable because MSCs secrete growth factors and cytokines that stimulate tissue regeneration, making them essential for developing functional skin grafts or engineered skin for burn victims. When combined with other biomaterials, MSCs may support various applications within orthopedics and dental regeneration.
Likewise, the cosmeceutical market is rapidly embracing MSC-derived products, particularly exosomes, to capitalize on their anti-aging and regenerative benefits. Major companies like L’Oréal and Johnson & Johnson are making significant investments in this area. Likewise, cultured meat companies are utilizing MSCs to produce muscle and fat cells, improving taste and texture. Groundbreaking approvals, such as lab-grown chicken by Upside Foods and Good Meat, have paved the way for further industry expansion.
MSC-based gene editing is also advancing, enabling the overexpression of antitumor genes and therapeutic factors. Researchers are exploring the potential of MSCs in 3D printing and engineered organ production, with significant breakthroughs expected in the coming decade.
Notably, companies like Cynata Therapeutics are at the forefront of iPSC-derived MSC production technologies, allowing for large-scale therapeutic development. Currently, at least eight companies are working on the development of iPSC-derived MSC therapeutics (iMSCs), including Cynata Therapeutics, Eterna Therapeutics, Implant Therapeutics, Bone Therapeutics, Brooklyn ImmunoTherapeutics, Fujifilm CDI, Citius Pharmaceuticals, and Kiji Therapeutics.
The Future Potential of MSCs
While the commercialization of MSCs faces challenges—such as achieving scalable production, ensuring consistent quality, and navigating complex regulatory approval processes—there are significant opportunities on the horizon. The market for MSC-based products is expected to experience substantial growth over the next decade, driven by their applications across a wide range of industries, such as research, therapeutic, cosmetic, and food industries. MSC-derived exosomes are also receiving substantial investment and attention
In research, MSCs are pivotal for studying regenerative medicine and disease modeling. In therapeutics, they hold promise for treating inflammatory, degenerative, and immune-related conditions. The cosmetic industry is exploring MSC-derived products for skin rejuvenation and anti-aging therapies. Finally, the food industry is beginning to investigate the potential for use of MSC-derived products, such as lab-grown muscle and fat cells, within its cell-based meat and functional supplements.
In aggregate, these exciting applications highlight the versatility and transformative potential of MSCs.
Tell Us What You Think!